<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "journalpublishing3.dtd">
<article xml:lang="en" article-type="research-article" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">IJO</journal-id>
<journal-title-group>
<journal-title>International Journal of Oncology</journal-title></journal-title-group>
<issn pub-type="ppub">1019-6439</issn>
<issn pub-type="epub">1791-2423</issn>
<publisher>
<publisher-name>D.A. Spandidos</publisher-name></publisher></journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3892/ijo.2014.2392</article-id>
<article-id pub-id-type="publisher-id">ijo-45-01-0104</article-id>
<article-categories>
<subj-group>
<subject>Articles</subject></subj-group></article-categories>
<title-group>
<article-title>The PTEN/PI3K/Akt and Wnt/&#x003B2;-catenin signaling pathways are involved in the inhibitory effect of resveratrol on human colon cancer cell proliferation</article-title></title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>LIU</surname><given-names>YING-ZI</given-names></name><xref rid="af1-ijo-45-01-0104" ref-type="aff"><sup>1</sup></xref><xref rid="af2-ijo-45-01-0104" ref-type="aff"><sup>2</sup></xref></contrib>
<contrib contrib-type="author">
<name><surname>WU</surname><given-names>KE</given-names></name><xref rid="af1-ijo-45-01-0104" ref-type="aff"><sup>1</sup></xref><xref rid="af2-ijo-45-01-0104" ref-type="aff"><sup>2</sup></xref></contrib>
<contrib contrib-type="author">
<name><surname>HUANG</surname><given-names>JUN</given-names></name><xref rid="af1-ijo-45-01-0104" ref-type="aff"><sup>1</sup></xref><xref rid="af2-ijo-45-01-0104" ref-type="aff"><sup>2</sup></xref></contrib>
<contrib contrib-type="author">
<name><surname>LIU</surname><given-names>YANG</given-names></name><xref rid="af1-ijo-45-01-0104" ref-type="aff"><sup>1</sup></xref><xref rid="af2-ijo-45-01-0104" ref-type="aff"><sup>2</sup></xref></contrib>
<contrib contrib-type="author">
<name><surname>WANG</surname><given-names>XIN</given-names></name><xref rid="af1-ijo-45-01-0104" ref-type="aff"><sup>1</sup></xref><xref rid="af4-ijo-45-01-0104" ref-type="aff"><sup>4</sup></xref></contrib>
<contrib contrib-type="author">
<name><surname>MENG</surname><given-names>ZI-JUN</given-names></name><xref rid="af1-ijo-45-01-0104" ref-type="aff"><sup>1</sup></xref><xref rid="af4-ijo-45-01-0104" ref-type="aff"><sup>4</sup></xref></contrib>
<contrib contrib-type="author">
<name><surname>YUAN</surname><given-names>SHUANG-XUE</given-names></name><xref rid="af1-ijo-45-01-0104" ref-type="aff"><sup>1</sup></xref><xref rid="af2-ijo-45-01-0104" ref-type="aff"><sup>2</sup></xref></contrib>
<contrib contrib-type="author">
<name><surname>WANG</surname><given-names>DONG-XU</given-names></name><xref rid="af1-ijo-45-01-0104" ref-type="aff"><sup>1</sup></xref><xref rid="af2-ijo-45-01-0104" ref-type="aff"><sup>2</sup></xref></contrib>
<contrib contrib-type="author">
<name><surname>LUO</surname><given-names>JIN-YONG</given-names></name><xref rid="af3-ijo-45-01-0104" ref-type="aff"><sup>3</sup></xref></contrib>
<contrib contrib-type="author">
<name><surname>ZUO</surname><given-names>GUO-WEI</given-names></name><xref rid="af3-ijo-45-01-0104" ref-type="aff"><sup>3</sup></xref></contrib>
<contrib contrib-type="author">
<name><surname>YIN</surname><given-names>LIANG-JUN</given-names></name><xref rid="af4-ijo-45-01-0104" ref-type="aff"><sup>4</sup></xref></contrib>
<contrib contrib-type="author">
<name><surname>CHEN</surname><given-names>LIANG</given-names></name><xref rid="af4-ijo-45-01-0104" ref-type="aff"><sup>4</sup></xref></contrib>
<contrib contrib-type="author">
<name><surname>DENG</surname><given-names>ZHONG-LIANG</given-names></name><xref rid="af4-ijo-45-01-0104" ref-type="aff"><sup>4</sup></xref></contrib>
<contrib contrib-type="author">
<name><surname>YANG</surname><given-names>JUN-QIN</given-names></name><xref rid="af1-ijo-45-01-0104" ref-type="aff"><sup>1</sup></xref><xref rid="af2-ijo-45-01-0104" ref-type="aff"><sup>2</sup></xref></contrib>
<contrib contrib-type="author">
<name><surname>SUN</surname><given-names>WEN-JUAN</given-names></name><xref rid="af1-ijo-45-01-0104" ref-type="aff"><sup>1</sup></xref><xref rid="af2-ijo-45-01-0104" ref-type="aff"><sup>2</sup></xref></contrib>
<contrib contrib-type="author">
<name><surname>HE</surname><given-names>BAI-CHENG</given-names></name><xref ref-type="corresp" rid="c1-ijo-45-01-0104"/><xref rid="af1-ijo-45-01-0104" ref-type="aff"><sup>1</sup></xref><xref rid="af2-ijo-45-01-0104" ref-type="aff"><sup>2</sup></xref></contrib></contrib-group>
<aff id="af1-ijo-45-01-0104">
<label>1</label>Chongqing Municipal Key Laboratory of Higher Education Institutions for Biochemistry and Molecular Pharmacology; Chongqing Medical University; Chongqing, 
<country>P.R. China</country></aff>
<aff id="af2-ijo-45-01-0104">
<label>2</label>Department of Pharmacology, School of Pharmacy, Chongqing Medical University; Chongqing, 
<country>P.R. China</country></aff>
<aff id="af3-ijo-45-01-0104">
<label>3</label>Key Laboratory for Diagnostic Medicine designated by the Chinese Ministry of Education, Chongqing Medical University; Chongqing, 
<country>P.R. China</country></aff>
<aff id="af4-ijo-45-01-0104">
<label>4</label>Department of Orthopedic Surgery, Second Affiliated Hospital, Chongqing Medical University, Chongqing, 
<country>P.R. China</country></aff>
<author-notes>
<corresp id="c1-ijo-45-01-0104">Correspondence to: Professor Bai-Cheng He, Department of Pharmacology, Chongqing Medical University, 1 Yixueyuan Road, Yuzhong, Chongqing 400016, P.R. China, E-mail: <email>hebaicheng99@yahoo.com</email></corresp></author-notes>
<pub-date pub-type="collection">
<month>7</month>
<year>2014</year></pub-date>
<pub-date pub-type="epub">
<day>17</day>
<month>04</month>
<year>2014</year></pub-date>
<volume>45</volume>
<issue>1</issue>
<fpage>104</fpage>
<lpage>112</lpage>
<history>
<date date-type="received">
<day>16</day>
<month>01</month>
<year>2014</year></date>
<date date-type="accepted">
<day>11</day>
<month>03</month>
<year>2014</year></date></history>
<permissions>
<copyright-statement>Copyright &#x000A9; 2014, Spandidos Publications</copyright-statement>
<copyright-year>2014</copyright-year>
<license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/3.0">
<license-p>This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.</license-p></license></permissions>
<abstract>
<p>Colon cancer is one of the most common malignancies and the treatments for colon cancer have been developed substantially in the last decades, but there is still a great clinical need to explore new treatment regimens due to the undesirable prognosis. In this investigation, we demonstrated the anti-proliferative and apoptosis-inducing activities of resveratrol (Res) in human colon cancer cells, and the possible mechanisms underlying these effects. We used crystal violet staining, flow cytometry and western blotting to validate the anti-proliferative and apoptosis-inducing effects of Res on HCT116 cells. A xenograft tumor model was used to confirm the anti-proliferative effects of Res. We employed polymerase chain reaction, western blotting, recombinant adenovirus and luciferase reporter assay to explore the possible mechanism(s) of action. We found that Res inhibits significantly the proliferation and promotes apoptosis in HCT116 cells, as well as inhibits the xenograft tumor growth of colon cancer. Res upregulates the expression of phosphatase and tensin homolog (PTEN) and decreases the phosphorylation of Akt1/2. The exogenous expression of PTEN inhibits the PI3K/Akt signal and promotes the anti-proliferative effects of Res in HCT116 cells, while knockdown of PTEN increases PI3K/Akt signal but reduces the anti-proliferative function of Res. The protein and mRNA expression of &#x003B2;-catenin are all decreased by Res concentration-dependently. Thus, our findings strongly suggest that the anti-proliferative effects of Res in human colon cancer cells may be mediated by regulating separately the PTEN/PI3K/Akt and Wnt/&#x003B2;-catenin signaling.</p></abstract>
<kwd-group>
<kwd>resveratrol</kwd>
<kwd>colon cancer</kwd>
<kwd>anti-proliferation</kwd>
<kwd>PTEN/PI3K</kwd>
<kwd>Akt</kwd>
<kwd>Wnt/&#x003B2;-catenin</kwd></kwd-group></article-meta></front>
<body>
<sec sec-type="intro">
<title>Introduction</title>
<p>Colorectal cancer (CRC) is one of the most common malignancies. The incidence of colon cancer shows an increasing trend with tendency for younger age (<xref rid="b1-ijo-45-01-0104" ref-type="bibr">1</xref>). The treatments of colon cancer including surgery resection or radiotherapy combined with chemotherapy (<xref rid="b2-ijo-45-01-0104" ref-type="bibr">2</xref>). However, these treatments improved patient survival with the decreasing of life quality. Thus, there is an urgent clinic need to develop new treatment regimens for colon cancer.</p>
<p>Natural products are widely accepted as validated agents for many conditions (<xref rid="b3-ijo-45-01-0104" ref-type="bibr">3</xref>&#x02013;<xref rid="b6-ijo-45-01-0104" ref-type="bibr">6</xref>). Many herbs or their components have already been used clinically as potential candidates for anticancer drugs, including anthocyanidins, catechins, quercetin and genistein (<xref rid="b7-ijo-45-01-0104" ref-type="bibr">7</xref>,<xref rid="b8-ijo-45-01-0104" ref-type="bibr">8</xref>). A few studies and clinical epidemiologic studies indicated that red wine has apparent effect on reducing the risks of cardiovascular diseases and cancer (<xref rid="b9-ijo-45-01-0104" ref-type="bibr">9</xref>,<xref rid="b10-ijo-45-01-0104" ref-type="bibr">10</xref>). Polyphenolic compounds are present at high levels in red wine, which may mainly contribute to the benefits of red wine.</p>
<p>Resveratrol (3,5,4&#x02032;-trihydroxystilbene, Res), as a natural polyphenolic compound mostly from beans and grapes, was discovered in red wine by Siemann and Creasy in 1992 (<xref rid="b11-ijo-45-01-0104" ref-type="bibr">11</xref>), and can be used as inhibitor for platelet aggregation, cardiac-protection and as anticancer agent (<xref rid="b10-ijo-45-01-0104" ref-type="bibr">10</xref>,<xref rid="b12-ijo-45-01-0104" ref-type="bibr">12</xref>). It has been reported also that Res can inhibit diet induced obesity (<xref rid="b13-ijo-45-01-0104" ref-type="bibr">13</xref>) inhibiting proliferation and promoting apoptosis in various tumor cells, such as colon cancer, breast cancer and prostate cancer cells <italic>in vitro</italic> and <italic>in vivo</italic> (<xref rid="b14-ijo-45-01-0104" ref-type="bibr">14</xref>&#x02013;<xref rid="b20-ijo-45-01-0104" ref-type="bibr">20</xref>). For colon cancer cells, the anti-proliferation and apoptotic inducing effects of Res have already been validated, but the mechanism underlying these activities remains unclear.</p>
<p>PI3K/Akt signaling plays a critical role in modulating cell survival and apoptosis (<xref rid="b21-ijo-45-01-0104" ref-type="bibr">21</xref>), it has been found over-activated in many cancers reducing apoptosis and promoting proliferation. The PI3K/Akt signaling was regulated by many other factors, one of the major negative regulators is phosphatase and tensin homologue (PTEN). PTEN was identified as a tumor suppressor (<xref rid="b22-ijo-45-01-0104" ref-type="bibr">22</xref>,<xref rid="b23-ijo-45-01-0104" ref-type="bibr">23</xref>), which is often deleted or mutated in a variety of cancers at high frequency (<xref rid="b24-ijo-45-01-0104" ref-type="bibr">24</xref>,<xref rid="b25-ijo-45-01-0104" ref-type="bibr">25</xref>). PTEN protein acts as a phosphatase specifically catalyzing the dephosphorylation of the 3-phosphate of the inositol ring in phosphatidylinositol (<xref rid="b3-ijo-45-01-0104" ref-type="bibr">3</xref>,<xref rid="b4-ijo-45-01-0104" ref-type="bibr">4</xref>,<xref rid="b5-ijo-45-01-0104" ref-type="bibr">5</xref>)-trisphosphate (PIP3), leading to the biphosphate product PIP2. The dephosphorylation of PIP3 results in the inactivation of PI3K/Akt signal pathway because PIP3 is critical in activation of Akt (<xref rid="b26-ijo-45-01-0104" ref-type="bibr">26</xref>).</p>
<p>Wnt/&#x003B2;-catenin signaling pathway is important for cell proliferation and differentiation, its aberrant activation is another major cause of colon cancer. The Wnt/&#x003B2;-catenin signaling can be upregulated by the phosphorylation of glycogen synthase 3 kinase &#x003B2; (GSK3&#x003B2;), an important negative regulator for Wnt/&#x003B2;-catenin signaling pathway, when PI3K/Akt signal is activated (<xref rid="b27-ijo-45-01-0104" ref-type="bibr">27</xref>,<xref rid="b28-ijo-45-01-0104" ref-type="bibr">28</xref>).</p>
<p>Herein, we investigated the possible molecular mechanism underlying the proliferation inhibitory and apoptosis inducing activities of Res in colon cancer cells. We found that Res exhibits prominent anti-proliferation and apoptosis inducing activity in HCT116 cells. Mechanistically, we demonstrated that Res can upregulate the expression of PTEN and inhibit the activation of PI3K/Akt signaling pathway, as well as to inhibit the Wnt/&#x003B2;-catenin signaling transduction, respectively. Our results support that Res can be used as anticancer agent alone or combined with other agents in colon cancer treatment.</p></sec>
<sec sec-type="methods">
<title>Materials and methods</title>
<sec>
<title>Reagents and cell culture</title>
<p>Resveratrol (Res) was purchased from Xi&#x02019;an Haoxuan Biotechnology Co. Ltd., (Xi&#x02019;an, China), and dissolved with dimethyl sulfoxide (DMSO). The aliquots were kept at &#x02212;20&#x000B0;C. VO-OHpic was from Sigma-Aldrich (St. Louis, MO, USA). HCT116 cell line was kindly provided by Dr Bert Vogelstein (Johns Hopkins Oncology Center; Baltimore, MD, USA). For <italic>in vivo</italic> experiment, Res was prepared with 0.5&#x00025; carboxymethylcellulose sodium (CMCNa) as suspension. All antibodies were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA). Cells were maintained in the Dulbecco&#x02019;s modified Eagle&#x02019;s medium (DMEM) with 10&#x00025; fetal bovine serum (FBS), 100 U/ml of penicillin, and 100 <italic>&#x003BC;</italic>g/ml of streptomycin at 37&#x000B0;C in 5&#x00025; CO<sub>2</sub>.</p></sec>
<sec>
<title>Crystal violet viability assay</title>
<p>Crystal violet assay was conducted as previously described (<xref rid="b29-ijo-45-01-0104" ref-type="bibr">29</xref>). Experimentally, HCT116 cells were treated with indicated concentrations of Res. At 24, 48 or 72 h after treatment, cells were carefully washed with cold phosphate-buffered saline (PBS, 4&#x000B0;C) and stained with 0.5&#x00025; crystal violet formalin solution at room temperature for 20&#x02013;30 min. The stained cells were washed with water and air dried for imaging and quantification. For quantification, the crystal violet was dissolved in 20&#x00025; acetic acid at room temperature for 20 min with shaking. The absorbance at 570 nm was measured (<xref rid="b30-ijo-45-01-0104" ref-type="bibr">30</xref>).</p></sec>
<sec>
<title>Flow cytometry analysis for cell cycle and apoptosis</title>
<p>Cells were seeded into 6-well plates. For cell cycle analysis, cells were treated with different concentrations of Res or solvent for 48 h. Then, cells were washed with PBS, collected and washed with cold (4&#x000B0;C) 70&#x00025; ethanol followed by washing with 50&#x00025;, 30&#x00025; ethanol and PBS; incubated with 1 ml of 20 mg/ml propidium iodide (PI) containing RNase (1 mg/ml) in PBS for 30 min followed by fluorescence activated cell sorting (FACS) assay. For apoptosis measure, cells were harvested after treated with different concentrations of Res for 48 h. Then, cells were washed with PBS (4&#x000B0;C), followed by incubating with Annexin V-EGFP and PI as the kit procedures (KeyGen Biotech Co. Ltd., Nanjing, China). Then, the cells were subjected to FACS assay.</p></sec>
<sec>
<title>Western blot assay</title>
<p>Cells were seeded in 6-well plates and treated with different concentrations of Res or solvent. At the scheduled time point, cells were lysed and the lysate were denatured by boiling for 10 min. Total protein were separated by SDS-PAGE, transfered with polyvinylidene difluoride (PVDF) membrane, blocked in 10&#x00025; skimmed milk and probed with antibody against the target proteins. Finally, the images of target bands were developed with SuperSignal West Pico Chemiluminescent substrate.</p></sec>
<sec>
<title>RNA isolation and reverse transcription polymerase chain reaction (RT-PCR)</title>
<p>Cells were seeded in T25 flask and treated with different concentrations of Res. The total RNA was extracted with TRIzol reagents (Invitrogen, Carlsbad, CA, USA), followed by reverse transcriptional reaction to obtain the cDNA product. Finally, the cDNA products were used as PCR templates to detect the target gene expression. The primer sequences are available upon request.</p></sec>
<sec>
<title>Construction of recombinant adenoviruses for exogenous expression of PTEN, GFP and knockdown siRNA fragments for PTEN</title>
<p>Recombinant adenoviruses for exogenous expression of PTEN (Ad-PTEN) or GFP (Ad-GFP) were generated with the AdEasy system as previously described (<xref rid="b31-ijo-45-01-0104" ref-type="bibr">31</xref>) as well as the recombinant adenoviruses expressing small interference RNA (siRNA) fragments for PTEN silence (Ad-siPTEN). Recombinant adenovirus expressing GFP was used as the vector control.</p></sec>
<sec>
<title>Xenograft tumor model of human colon cancer and histological evaluation</title>
<p>All animal experiments followed the guidelines of Institutional Animal Care and Use Committee of Chongqing Medical University (Chongqing, China). Athymic nude mice (female, 4&#x02013;6 weeks old, 5/group) were from the animal center of Chongqing Medical University (Chongqing, China). HCT116 cells were cultured and resuspended in PBS for subcutaneous injection (1&#x000D7;10<sup>6</sup>/injection) into the flanks of the athymic nude mice. The mice were treated with Res (50 or 150 mg/kg) or the same volume of solvent through intragastric administration one week after cancer cell injection, once a day for four weeks. At the end of the 4th week, all nude mice were sacrificed, the tumor samples were retrieved and fixed in 10&#x00025; formalin, and then embedded in paraffin. Serial sections of the embedded samples were stained with hematoxylin and eosin (H&amp;E).</p></sec>
<sec>
<title>Luciferase reporter assay</title>
<p>Firefly luciferase reporter assay was carried out as follows. Cells were seeded in T25 flasks and transfected with 3.0 <italic>&#x003BC;</italic>g per flask of pTOP-Luc (&#x003B2;-catenin/Tcf4 responsive elements reporter plasmid) using Lipofectamine (Invitrogen). After 12 h, cells were replated in 24-well plates and treated with different concentrations of Res or solvent as control. After 24 h, cells were lysed and subjected to luciferase activity assays following the manual of the kit (Promega, Madison, WI, USA). Luciferase activity was normalized with total cellular protein concentrations of the samples. Each assay was done in triplicate.</p></sec>
<sec>
<title>Statistical analysis</title>
<p>All experiments were performed in triplicates and the results were repeated in at least two independent experiments. Statistical analysis of results was conducted using t-test (Microsoft Excel). Data are expressed as mean &#x000B1; standard deviation (SD). Statistical significance was set at P&lt;0.05.</p></sec></sec>
<sec sec-type="results">
<title>Results</title>
<sec>
<title>Resveratrol inhibits the proliferation in colon cancer cells</title>
<p>It has been reported that Res inhibits the proliferation of various cancer cells and modulates the processes of cancer (<xref rid="b32-ijo-45-01-0104" ref-type="bibr">32</xref>). To investigate whether Res can affect the proliferation of human colon cancer, we analyzed the effect of Res on proliferation in human colon cancer cells. The results indicate that Res can inhibit the proliferation of HCT116 and SW480 cells concentration-dependently (<xref rid="f1-ijo-45-01-0104" ref-type="fig">Fig. 1A and B</xref>). Cell cycle analysis shows that Res can arrest the cell cycle at G1 phase in HCT116 cells (<xref rid="f1-ijo-45-01-0104" ref-type="fig">Fig. 1C</xref>). For further testing, we detected the effect of Res on the expression of proliferating cell nuclear antigen (PCNA) in HCT116 cells. The result shows that Res decreases the expression of PCNA concentration-dependently in HCT116 cells (<xref rid="f1-ijo-45-01-0104" ref-type="fig">Fig. 1D</xref>). These data demonstrate that Res is able to inhibit the proliferation of HCT116 cells.</p></sec>
<sec>
<title>Resveratrol induces apoptosis in colon cancer cells</title>
<p>Most anticancer agents have characteristics of apoptosis induction, so we tested whether Res could induce apoptosis in HCT116 cells. We employed Annexin V staining, FACS and western blotting to assay the effect of Res on apoptosis in HCT116 cells. The results show that Res can induce apoptosis clearly and concentration-dependently (<xref rid="f2-ijo-45-01-0104" ref-type="fig">Fig. 2A and B</xref>). Western blot assay results indicate that the protein level of caspase-3 increased substantially (<xref rid="f2-ijo-45-01-0104" ref-type="fig">Fig. 2C</xref>). These results strongly suggest that Res is a potent apoptosis inducer for human colon cancer cells.</p></sec>
<sec>
<title>Resveratrol inhibits tumor growth in a xenograft tumor model</title>
<p>The above evidence has proven that Res is a potent proliferation inhibitor agent for colon cancer cells. We next investigated the <italic>in vivo</italic> anticancer activity of Res with a xenograft tumor model for colon cancer. We injected 1&#x000D7;10<sup>6</sup> HCT116 cells into flanks of athymic nude mice. One week after injection, we treated the mice with intragastric administration of Res (50 or 150 mg/kg), once a day for four weeks. The results show that tumor masses from mice treated with Res are smaller than those of the control group (<xref rid="f3-ijo-45-01-0104" ref-type="fig">Fig. 3A</xref>). The H&amp;E staining results indicate that Res treated groups exhibited a decreased cellularity in tumor masses (<xref rid="f3-ijo-45-01-0104" ref-type="fig">Fig. 3B</xref>) suggesting that Res can inhibit tumor growth <italic>in vivo</italic>, although it can not eliminated tumors completely.</p></sec>
<sec>
<title>PTEN is involved in the anti-proliferation effect of resveratrol in colon cancer cells</title>
<p>PTEN, as a tumor suppressor gene, has been found damaged or deficient in many cancer (<xref rid="b33-ijo-45-01-0104" ref-type="bibr">33</xref>&#x02013;<xref rid="b35-ijo-45-01-0104" ref-type="bibr">35</xref>). It may be one of the targets for anticancer treatment. Thus, we investigated whether PTEN is involved in the anti-proliferation effect of Res in human colon cancer cells. The PCR and western blot results show that Res can induce the expression of PTEN concentration-dependently (<xref rid="f4-ijo-45-01-0104" ref-type="fig">Fig. 4A and B</xref>). The PTEN inhibitor attenuates the anti-proliferation effect of Res in HCT116 cells (<xref rid="f4-ijo-45-01-0104" ref-type="fig">Fig. 4C</xref>). Exogenous expression of PTEN potentiates the proliferation inhibitory effect of Res, while knockdown of PTEN inhibits this effect of Res in HCT116 cells (<xref rid="f4-ijo-45-01-0104" ref-type="fig">Fig. 4D</xref>). These results indicate that PTEN is involved in the anti-proliferation of Res in human colon cancer cells.</p></sec>
<sec>
<title>Resveratrol downregulates PI3K/Akt signaling in HCT116 cells through upregulating PTEN</title>
<p>One major function of PTEN is to negatively regulate PI3K/Akt signaling. The PI3K/Akt signaling pathway is one of the essential pathways for cell survival and proliferation, which is over-activated in many human cancers, such as breast, colon and prostate cancers (<xref rid="b10-ijo-45-01-0104" ref-type="bibr">10</xref>,<xref rid="b14-ijo-45-01-0104" ref-type="bibr">14</xref>). Thus, we investigated whether PI3K/Akt signaling is involved in the anti-proliferation effect of Res in HCT116 cells. The results indicated that Res has no apparent effect on the mRNA expression of Akt1 and Akt2 (<xref rid="f5-ijo-45-01-0104" ref-type="fig">Fig. 5A</xref>), but can reduce the phosphorylation level of Akt1/2 concentration-dependently (<xref rid="f5-ijo-45-01-0104" ref-type="fig">Fig. 5B</xref>). Res combined with adenovirus mediated exogenous expression of PTEN decreases the phosphorylation of Akt1/2 substantially (<xref rid="f5-ijo-45-01-0104" ref-type="fig">Fig. 5C</xref>), while knockdown of PTEN reverses the effect of Res on the phosphorylation of Akt1/2 (<xref rid="f5-ijo-45-01-0104" ref-type="fig">Fig. 5D</xref>). These results suggest that Res can inhibit PI3K/Akt signaling activation in HCT116 cells through the upregulation of PTEN.</p></sec>
<sec>
<title>Resveratrol inhibits Wnt/&#x003B2;-catenin signaling transduction independent of PTEN/PI3K/Akt in HCT116 cells</title>
<p>The abnormal activation of Wnt/&#x003B2;-catenin signaling is one of the major causes of cancer, which can be regulated by PTEN/PI3K/Akt signaling through the phosphorylation of GSK-3&#x003B2;. HCT116 cells are predisposed to the mutation of &#x003B2;-catenin, thus, it can not be degradated by the degradative complex in the canonical Wnt signaling pathway. We measured whether Res could still decrease the level of &#x003B2;-catenin in HCT116 cells. We found that Res has no apparent effect on the total level of GSK-3&#x003B2;, but decreases the phosphorylation of GSK-3&#x003B2; substantially, as well as the protein level of &#x003B2;-catenin (<xref rid="f6-ijo-45-01-0104" ref-type="fig">Fig. 6A</xref>). The &#x003B2;-catenin/Tcf4 reporter assay results indicate that Res inhibited the reporter activity concentration-dependently (<xref rid="f6-ijo-45-01-0104" ref-type="fig">Fig. 6B</xref>). Moreover, the &#x003B2;-catenin mRNA expression was also decreased by Res (<xref rid="f6-ijo-45-01-0104" ref-type="fig">Fig. 6C</xref>). These results suggest that the canonical Wnt signaling pathway is involved in the anti-proliferation effect of Res in HCT116 cells.</p></sec></sec>
<sec sec-type="discussion">
<title>Discussion</title>
<p>Colon cancer is one of the most frequently diagnosed malignancies, with high incidence in western countries (<xref rid="b1-ijo-45-01-0104" ref-type="bibr">1</xref>). Although the treatment for colon cancer has advanced substantially, the prognosis is still more modest than had been hoped (<xref rid="b36-ijo-45-01-0104" ref-type="bibr">36</xref>). There is a great clinical need to explore new treatment regimens for colon cancer. In this investigation, we demonstrated that Res has potent anti-proliferation activity in human colon cancer cells, and the anti-proliferation effect of Res may be mediated by inhibiting PI3K/Akt signaling through upregulating the expression of PTEN and blocking Wnt/&#x003B2;-catenin signaling transduction, respectively.</p>
<p>Res, as a natural polyphenolic compound, is found in the skin of red grapes and other fruits as well as in Japanese knotweed roots (<xref rid="b11-ijo-45-01-0104" ref-type="bibr">11</xref>). Several studies have proved that Res can inhibit proliferation and induce apoptosis of breast cancer cells, prostate cancer cells and colon cancer cells (<xref rid="b10-ijo-45-01-0104" ref-type="bibr">10</xref>,<xref rid="b13-ijo-45-01-0104" ref-type="bibr">13</xref>,<xref rid="b14-ijo-45-01-0104" ref-type="bibr">14</xref>). No clinical trial has yet reported the cancer prevention effect of Res (<xref rid="b37-ijo-45-01-0104" ref-type="bibr">37</xref>). Moreover, the bioavailability of Res is very low, so even a high dose of Res may not reach the sufficient concentration required for systemic treatment for cancers (<xref rid="b38-ijo-45-01-0104" ref-type="bibr">38</xref>), however, this may be a benefit for digestive tract cancer treatment. Our <italic>in vitro</italic> results show that Res can inhibit the proliferation of HCT116 cells, even at the concentration of 20 <italic>&#x003BC;</italic>M. These data confirmed that Res has the potential to be an anticancer agent. Interestingly, our investigation indicates that Res shows no apparent proliferation inhibitory effect in HEK-293 cells, even at the concentration of 100 <italic>&#x003BC;</italic>M (data not shown). This result implies that the anti-proliferation effect of Res may be more specific to cancer cells.</p>
<p>The above studies, and our new results validate the proliferation inhibitory effect of Res on colon cancer cells, but the exact molecular mechanism underlying this remains unknown. Vanamala <italic>et al</italic> reported that Res could induce apoptosis through the suppression of Wnt pathway and activation of p53 signaling pathways in human colon cancer (<xref rid="b39-ijo-45-01-0104" ref-type="bibr">39</xref>). The expression of MicroRNA-21 participates in the inhibition of prostate cancer growth and metastasis initialized by Res (<xref rid="b16-ijo-45-01-0104" ref-type="bibr">16</xref>). Recent studies indicate that p38 and PI3K signaling pathways are involved in the anticancer activity of Res (<xref rid="b40-ijo-45-01-0104" ref-type="bibr">40</xref>). Wnt, PI3K/Akt and p38 signaling pathways are all essential for cell proliferation and differentiation, and found to be aberrant in many cancers. However, the exact molecular mechanism of how Res regulates these signaling pathways remains unclear.</p>
<p>PTEN, a tumor suppressor often mutated or lost in many cancers, acts as a phosphatase to specifically catalyse PIP3 dephosphorylation at the 3-phosphate of the inositol ring and turn PIP3 to PIP2 through which it negatively regulates PI3K/Akt signaling. PI3K/Akt signaling has been associated with many cellular functions, including proliferation, differentiation, motility and survival. Previous studies indicated that PTEN may play an important role in early stages of sporadic colorectal carcinogenesis and reduced or lost PTEN expression is more frequent in colon cancer (<xref rid="b25-ijo-45-01-0104" ref-type="bibr">25</xref>); colon cancer cells with high expression of PTEN is correlated with chemosensitivity (<xref rid="b41-ijo-45-01-0104" ref-type="bibr">41</xref>). Our results show that Res can up regulate the expression of PTEN in HCT116 cells. Either PTEN specific inhibitor or knockdown of PTEN can attenuate the anti-proliferation effect of Res in HCT116 cells, while exogenous expression of PTEN can potentiate the proliferation inhibitory effect of Res in these cells. These data indicate that PTEN may be important for the anti-proliferation effect of Res in HCT116 cells. Further analysis confirmed that the up regulated PTEN by Res is correlated with the inactivation of PI3K/Akt signaling by decreasing the phosphorylation of Akt1/2 in HCT116 cells. Therefore, our results suggest that PTEN/PI3K/Akt is involved in the proliferation inhibitory effect of Res in HCT116 cells.</p>
<p>Another major cause of colon cancer is the over activated Wnt/&#x003B2;-catenin signaling pathway. Most colon cancer cells are predisposed to the mutation of &#x003B2;-catenin or APC (<xref rid="b42-ijo-45-01-0104" ref-type="bibr">42</xref>). Wnt signaling, including canonical and noncanonical Wnt signaling, plays an important role in embryogenesis and development. The &#x003B2;-catenin plays a pivotal role in canonical Wnt signaling. In the absence of Wnt proteins, Axin, GSK-3&#x003B2; and APC assemble as a complex to promote the proteolytic degradation of &#x003B2;-catenin. When Wnt proteins bind with the frizzled receptor, the degradation complex will be destroyed and the &#x003B2;-catenin can be accumulated in the cytoplasm and translocate to the nucleus. Eventually, &#x003B2;-catenin interacts with TCF/LEF transcription factors to regulate the downstream gene expression.</p>
<p>The mutation of APC, &#x003B2;-catenin or phosphorylation of GSK-3&#x003B2; cause &#x003B2;-catenin not to be degraded normally by the destruction complex and accumulate in the cytoplasm. The activation of PI3K/Akt can activate the canonical Wnt signaling through the phosphorylation of GSK-3&#x003B2; by the phosphorylated Akt1/2, blocking the formation of &#x003B2;-catenin destroying complex (<xref rid="b28-ijo-45-01-0104" ref-type="bibr">28</xref>). Hence, the upregulation of PTEN may inhibit the canonical Wnt signaling by promoting the degradation of &#x003B2;-catenin. Although our results show that Res can decrease the phosphorylation of GSK-3&#x003B2;, the protein level of &#x003B2;-catenin, and the &#x003B2;-catenin/Tcf4 reporter activity, but it may not result from the decreased phosphorylation of GSK-3&#x003B2; by PTEN/PI3K/Akt signaling. As it is predisposed to mutation of &#x003B2;-catenin in HCT116 cells, the &#x003B2;-catenin can not be degraded by the destruction complex in this colon cancer cells. With additional investigation, we unveiled that Res can inhibit the mRNA expression of &#x003B2;-catenin. Thus, these results suggest that Res can inhibit the Wnt/&#x003B2;-catenin signaling transduction, but it may not result from the upregulation of PTEN in HCT116 cells.</p>
<p>Taken together, Our data strongly suggest that Res can inhibit the proliferation and promote apoptosis in colon cancer cells. These activities of Res may be mediated by PI3K/Akt signaling through upregulating the expression of PTEN and reducing the Wnt/&#x003B2;-catenin signaling transduction through inhibiting the expression of &#x003B2;-catenin, respectively. However, the detailed molecular mechanism of how Res regulate the expression of PTEN and &#x003B2;-catenin need to be further deciphered.</p></sec></body>
<back>
<ack>
<p>We thank Dr Bert Vogelstein of the Johns Hopkins Oncology Center (Baltimore, MD, USA) for his kind provision of HCT116 cells. We thank Professor Qi-Xin Zhou of Chongqing Medical University (Chongqing, China) for his critical reading of the manuscript. This study was supported in part by research grants from Natural Science Foundation of China (Grants: NSFC 81071462 and 81372120), Chongqing Science &amp; Technology Commission of China (Grant: CSTC 2011BB5129), and the National Basic Research Program of China (Grant: 2011CB70790).</p></ack>
<ref-list>
<title>References</title>
<ref id="b1-ijo-45-01-0104"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brunagel</surname><given-names>G</given-names></name><name><surname>Vietmeier</surname><given-names>BN</given-names></name><name><surname>Bauer</surname><given-names>AJ</given-names></name><name><surname>Schoen</surname><given-names>RE</given-names></name><name><surname>Getzenberg</surname><given-names>RH</given-names></name></person-group><article-title>Identification of nuclear matrix protein alterations associated with human colon cancer</article-title><source>Cancer Res</source><volume>62</volume><fpage>2437</fpage><lpage>2442</lpage><year>2002</year></element-citation></ref>
<ref id="b2-ijo-45-01-0104"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fey</surname><given-names>MF</given-names></name></person-group><article-title>Adjuvant therapy for colon cancer</article-title><source>Schweiz Med Wochenschr</source><volume>130</volume><fpage>1760</fpage><lpage>1765</lpage><year>2000</year><comment>(In German).</comment></element-citation></ref>
<ref id="b3-ijo-45-01-0104"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cragg</surname><given-names>GM</given-names></name><name><surname>Grothaus</surname><given-names>PG</given-names></name><name><surname>Newman</surname><given-names>DJ</given-names></name></person-group><article-title>Impact of natural products on developing new anti-cancer agents</article-title><source>Chem Rev</source><volume>109</volume><fpage>3012</fpage><lpage>3043</lpage><year>2009</year></element-citation></ref>
<ref id="b4-ijo-45-01-0104"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mishra</surname><given-names>BB</given-names></name><name><surname>Tiwari</surname><given-names>VK</given-names></name></person-group><article-title>Natural products: an evolving role in future drug discovery</article-title><source>Eur J Med Chem</source><volume>46</volume><fpage>4769</fpage><lpage>4807</lpage><year>2011</year></element-citation></ref>
<ref id="b5-ijo-45-01-0104"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zou</surname><given-names>DM</given-names></name><name><surname>Brewer</surname><given-names>M</given-names></name><name><surname>Garcia</surname><given-names>F</given-names></name><etal/></person-group><article-title>Cactus pear: a natural product in cancer chemoprevention</article-title><source>Nutr J</source><volume>4</volume><fpage>25</fpage><year>2005</year></element-citation></ref>
<ref id="b6-ijo-45-01-0104"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Konkimalla</surname><given-names>VB</given-names></name><name><surname>Efferth</surname><given-names>T</given-names></name></person-group><article-title>Anti-cancer natural product library from traditional Chinese medicine</article-title><source>Comb Chem High Throughput Screen</source><volume>11</volume><fpage>7</fpage><lpage>15</lpage><year>2008</year></element-citation></ref>
<ref id="b7-ijo-45-01-0104"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khan</surname><given-names>N</given-names></name><name><surname>Afaq</surname><given-names>F</given-names></name><name><surname>Mukhtar</surname><given-names>H</given-names></name></person-group><article-title>Cancer chemoprevention through dietary antioxidants: progress and promise</article-title><source>Antioxid Redox Signal</source><volume>10</volume><fpage>475</fpage><lpage>510</lpage><year>2008</year></element-citation></ref>
<ref id="b8-ijo-45-01-0104"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Korkina</surname><given-names>LG</given-names></name><name><surname>De Luca</surname><given-names>C</given-names></name><name><surname>Kostyuk</surname><given-names>VA</given-names></name><name><surname>Pastore</surname><given-names>S</given-names></name></person-group><article-title>Plant polyphenols and tumors: from mechanisms to therapies, prevention, and protection against toxicity of anti-cancer treatments</article-title><source>Curr Med Chem</source><volume>16</volume><fpage>3943</fpage><lpage>3965</lpage><year>2009</year></element-citation></ref>
<ref id="b9-ijo-45-01-0104"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Das</surname><given-names>S</given-names></name><name><surname>Santani</surname><given-names>DD</given-names></name><name><surname>Dhalla</surname><given-names>NS</given-names></name></person-group><article-title>Experimental evidence for the cardioprotective effects of red wine</article-title><source>Exp Clin Cardiol</source><volume>12</volume><fpage>5</fpage><lpage>10</lpage><year>2007</year></element-citation></ref>
<ref id="b10-ijo-45-01-0104"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jang</surname><given-names>M</given-names></name><name><surname>Cai</surname><given-names>L</given-names></name><name><surname>Udeani</surname><given-names>GO</given-names></name><etal/></person-group><article-title>Cancer chemopreventive activity of resveratrol, a natural product derived from grapes</article-title><source>Science</source><volume>275</volume><fpage>218</fpage><lpage>220</lpage><year>1997</year></element-citation></ref>
<ref id="b11-ijo-45-01-0104"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gehm</surname><given-names>BD</given-names></name><name><surname>McAndrews</surname><given-names>JM</given-names></name><name><surname>Chien</surname><given-names>PY</given-names></name><name><surname>Jameson</surname><given-names>JL</given-names></name></person-group><article-title>Resveratrol, a polyphenolic compound found in grapes and wine, is an agonist for the estrogen receptor</article-title><source>Proc Natl Acad Sci USA</source><volume>94</volume><fpage>14138</fpage><lpage>14143</lpage><year>1997</year></element-citation></ref>
<ref id="b12-ijo-45-01-0104"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bhat</surname><given-names>KPL</given-names></name><name><surname>Kosmeder</surname><given-names>JW</given-names><suffix>II</suffix></name><name><surname>Pezzuto</surname><given-names>JM</given-names></name></person-group><article-title>Biological effects of resveratrol</article-title><source>Antioxid Redox Signal</source><volume>3</volume><fpage>1041</fpage><lpage>1064</lpage><year>2001</year></element-citation></ref>
<ref id="b13-ijo-45-01-0104"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gulvady</surname><given-names>AA</given-names></name><name><surname>Ciolino</surname><given-names>HP</given-names></name><name><surname>Cabrera</surname><given-names>RM</given-names></name><name><surname>Jolly</surname><given-names>CA</given-names></name></person-group><article-title>Resveratrol inhibits the deleterious effects of diet-induced obesity on thymic function</article-title><source>J Nutr Biochem</source><volume>24</volume><fpage>1625</fpage><lpage>1633</lpage><year>2013</year></element-citation></ref>
<ref id="b14-ijo-45-01-0104"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fang</surname><given-names>JY</given-names></name><name><surname>Li</surname><given-names>ZH</given-names></name><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Huang</surname><given-names>WS</given-names></name><name><surname>Kang</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>JP</given-names></name></person-group><article-title>Resveratrol affects protein kinase C activity and promotes apoptosis in human colon carcinoma cells</article-title><source>Asian Pac J Cancer Prev</source><volume>13</volume><fpage>6017</fpage><lpage>6022</lpage><year>2012</year></element-citation></ref>
<ref id="b15-ijo-45-01-0104"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>R</given-names></name><name><surname>Serrero</surname><given-names>G</given-names></name></person-group><article-title>Resveratrol, a natural product derived from grape, exhibits antiestrogenic activity and inhibits the growth of human breast cancer cells</article-title><source>J Cell Physiol</source><volume>179</volume><fpage>297</fpage><lpage>304</lpage><year>1999</year></element-citation></ref>
<ref id="b16-ijo-45-01-0104"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sheth</surname><given-names>S</given-names></name><name><surname>Jajoo</surname><given-names>S</given-names></name><name><surname>Kaur</surname><given-names>T</given-names></name><etal/></person-group><article-title>Resveratrol reduces prostate cancer growth and metastasis by inhibiting the Akt/MicroRNA-21 pathway</article-title><source>PLoS One</source><volume>7</volume><fpage>e51655</fpage><year>2012</year></element-citation></ref>
<ref id="b17-ijo-45-01-0104"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fouad</surname><given-names>M</given-names></name><name><surname>Agha</surname><given-names>A</given-names></name><name><surname>Merzabani</surname><given-names>MA</given-names></name><name><surname>Shouman</surname><given-names>S</given-names></name></person-group><article-title>Resveratrol inhibits proliferation, angiogenesis and induces apoptosis in colon cancer cells: Calorie restriction is the force to the cytotoxicity</article-title><source>Hum Exp Toxicol</source><volume>32</volume><fpage>1067</fpage><lpage>1080</lpage><year>2013</year></element-citation></ref>
<ref id="b18-ijo-45-01-0104"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>HL</given-names></name><name><surname>Chen</surname><given-names>WQ</given-names></name><name><surname>Cao</surname><given-names>X</given-names></name><etal/></person-group><article-title>Caveolin-1 enhances resveratrol-mediated cytotoxicity and transport in a hepatocellular carcinoma model</article-title><source>J Transl Med</source><volume>7</volume><fpage>22</fpage><year>2009</year></element-citation></ref>
<ref id="b19-ijo-45-01-0104"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miura</surname><given-names>D</given-names></name><name><surname>Miura</surname><given-names>Y</given-names></name><name><surname>Yagasaki</surname><given-names>K</given-names></name></person-group><article-title>Hypolipidemic action of dietary resveratrol, a phytoalexin in grapes and red wine, in hepatoma-bearing rats</article-title><source>Life Sci</source><volume>73</volume><fpage>1393</fpage><lpage>1400</lpage><year>2003</year></element-citation></ref>
<ref id="b20-ijo-45-01-0104"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>HS</given-names></name><name><surname>Pan</surname><given-names>CE</given-names></name><name><surname>Yang</surname><given-names>W</given-names></name><name><surname>Liu</surname><given-names>XM</given-names></name></person-group><article-title>Antitumor and immunomodulatory activity of resveratrol on experimentally implanted tumor of H22 in Balb/c mice</article-title><source>World J Gastroenterol</source><volume>9</volume><fpage>1474</fpage><lpage>1476</lpage><year>2003</year></element-citation></ref>
<ref id="b21-ijo-45-01-0104"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fresno Vara</surname><given-names>JA</given-names></name><name><surname>Casado</surname><given-names>E</given-names></name><name><surname>de Castro</surname><given-names>J</given-names></name><name><surname>Cejas</surname><given-names>P</given-names></name><name><surname>Belda-Iniesta</surname><given-names>C</given-names></name><name><surname>Gonzalez-Baron</surname><given-names>M</given-names></name></person-group><article-title>PI3K/Akt signalling pathway and cancer</article-title><source>Cancer Treat Rev</source><volume>30</volume><fpage>193</fpage><lpage>204</lpage><year>2004</year></element-citation></ref>
<ref id="b22-ijo-45-01-0104"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mahimainathan</surname><given-names>L</given-names></name><name><surname>Choudhury</surname><given-names>GG</given-names></name></person-group><article-title>Inactivation of platelet-derived growth factor receptor by the tumor suppressor PTEN provides a novel mechanism of action of the phosphatase</article-title><source>J Biol Chem</source><volume>279</volume><fpage>15258</fpage><lpage>15268</lpage><year>2004</year></element-citation></ref>
<ref id="b23-ijo-45-01-0104"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takeda</surname><given-names>K</given-names></name><name><surname>Kanekura</surname><given-names>T</given-names></name><name><surname>Kanzaki</surname><given-names>T</given-names></name></person-group><article-title>Negative feedback regulation of phosphatidylinositol 3-kinase/Akt pathway by over-expressed cyclooxygenase-2 in human epidermal cancer cells</article-title><source>J Dermatol</source><volume>31</volume><fpage>516</fpage><lpage>523</lpage><year>2004</year></element-citation></ref>
<ref id="b24-ijo-45-01-0104"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chalhoub</surname><given-names>N</given-names></name><name><surname>Baker</surname><given-names>SJ</given-names></name></person-group><article-title>PTEN and the PI3-kinase pathway in cancer</article-title><source>Annu Rev Pathol</source><volume>4</volume><fpage>127</fpage><lpage>150</lpage><year>2009</year></element-citation></ref>
<ref id="b25-ijo-45-01-0104"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Waniczek</surname><given-names>D</given-names></name><name><surname>Snietura</surname><given-names>M</given-names></name><name><surname>Mlynarczyk-Liszka</surname><given-names>J</given-names></name><etal/></person-group><article-title>PTEN expression profiles in colorectal adenocarcinoma and its precancerous lesions</article-title><source>Pol J Pathol</source><volume>64</volume><fpage>15</fpage><lpage>20</lpage><year>2013</year></element-citation></ref>
<ref id="b26-ijo-45-01-0104"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Franke</surname><given-names>TF</given-names></name><name><surname>Kaplan</surname><given-names>DR</given-names></name><name><surname>Cantley</surname><given-names>LC</given-names></name><name><surname>Toker</surname><given-names>A</given-names></name></person-group><article-title>Direct regulation of the Akt proto-oncogene product by phosphatidylinositol-3,4-bisphosphate</article-title><source>Science</source><volume>275</volume><fpage>665</fpage><lpage>668</lpage><year>1997</year></element-citation></ref>
<ref id="b27-ijo-45-01-0104"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>N</given-names></name><etal/></person-group><article-title>Modulation of &#x003B2;-catenin signaling by the inhibitors of MAP kinase, tyrosine kinase, and PI3-kinase pathways</article-title><source>Int J Med Sci</source><volume>10</volume><fpage>1888</fpage><lpage>1898</lpage><year>2013</year></element-citation></ref>
<ref id="b28-ijo-45-01-0104"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robertson</surname><given-names>BW</given-names></name><name><surname>Chellaiah</surname><given-names>MA</given-names></name></person-group><article-title>Osteopontin induces beta-catenin signaling through activation of Akt in prostate cancer cells</article-title><source>Exp Cell Res</source><volume>316</volume><fpage>1</fpage><lpage>11</lpage><year>2010</year></element-citation></ref>
<ref id="b29-ijo-45-01-0104"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>BC</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Zuo</surname><given-names>GW</given-names></name><etal/></person-group><article-title>Synergistic antitumor effect of the activated PPARgamma and retinoid receptors on human osteosarcoma</article-title><source>Clin Cancer Res</source><volume>16</volume><fpage>2235</fpage><lpage>2245</lpage><year>2010</year></element-citation></ref>
<ref id="b30-ijo-45-01-0104"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stepanovic</surname><given-names>S</given-names></name><name><surname>Vukovic</surname><given-names>D</given-names></name><name><surname>Dakic</surname><given-names>I</given-names></name><name><surname>Savic</surname><given-names>B</given-names></name><name><surname>Svabic-Vlahovic</surname><given-names>M</given-names></name></person-group><article-title>A modified microtiter-plate test for quantification of staphylococcal biofilm formation</article-title><source>J Microbiol Methods</source><volume>40</volume><fpage>175</fpage><lpage>179</lpage><year>2000</year></element-citation></ref>
<ref id="b31-ijo-45-01-0104"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>TC</given-names></name><name><surname>Zhou</surname><given-names>S</given-names></name><name><surname>da Costa</surname><given-names>LT</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Kinzler</surname><given-names>KW</given-names></name><name><surname>Vogelstein</surname><given-names>B</given-names></name></person-group><article-title>A simplified system for generating recombinant adenoviruses</article-title><source>Proc Natl Acad Sci USA</source><volume>95</volume><fpage>2509</fpage><lpage>2514</lpage><year>1998</year></element-citation></ref>
<ref id="b32-ijo-45-01-0104"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Joe</surname><given-names>AK</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Suzui</surname><given-names>M</given-names></name><name><surname>Vural</surname><given-names>ME</given-names></name><name><surname>Xiao</surname><given-names>D</given-names></name><name><surname>Weinstein</surname><given-names>IB</given-names></name></person-group><article-title>Resveratrol induces growth inhibition, S-phase arrest, apoptosis, and changes in biomarker expression in several human cancer cell lines</article-title><source>Clin Cancer Res</source><volume>8</volume><fpage>893</fpage><lpage>903</lpage><year>2002</year></element-citation></ref>
<ref id="b33-ijo-45-01-0104"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pal</surname><given-names>I</given-names></name><name><surname>Mandal</surname><given-names>M</given-names></name></person-group><article-title>PI3K and Akt as molecular targets for cancer therapy: current clinical outcomes</article-title><source>Acta Pharmacol Sin</source><volume>33</volume><fpage>1441</fpage><lpage>1458</lpage><year>2012</year></element-citation></ref>
<ref id="b34-ijo-45-01-0104"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>MS</given-names></name><name><surname>Huang</surname><given-names>JX</given-names></name><name><surname>Chen</surname><given-names>WC</given-names></name><etal/></person-group><article-title>Expression of PPARgamma and PTEN in human colorectal cancer: An immunohistochemical study using tissue microarray methodology</article-title><source>Oncol Lett</source><volume>2</volume><fpage>1219</fpage><lpage>1224</lpage><year>2011</year></element-citation></ref>
<ref id="b35-ijo-45-01-0104"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garcia</surname><given-names>JM</given-names></name><name><surname>Silva</surname><given-names>JM</given-names></name><name><surname>Dominguez</surname><given-names>G</given-names></name><etal/></person-group><article-title>Allelic loss of the PTEN region (10q23) in breast carcinomas of poor pathophenotype</article-title><source>Breast Cancer Res Treat</source><volume>57</volume><fpage>237</fpage><lpage>243</lpage><year>1999</year></element-citation></ref>
<ref id="b36-ijo-45-01-0104"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aggarwal</surname><given-names>S</given-names></name><name><surname>Chu</surname><given-names>E</given-names></name></person-group><article-title>Current therapies for advanced colorectal cancer</article-title><source>Oncology</source><volume>19</volume><fpage>589</fpage><lpage>595</lpage><year>2005</year></element-citation></ref>
<ref id="b37-ijo-45-01-0104"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Athar</surname><given-names>M</given-names></name><name><surname>Back</surname><given-names>JH</given-names></name><name><surname>Tang</surname><given-names>X</given-names></name><etal/></person-group><article-title>Resveratrol: a review of preclinical studies for human cancer prevention</article-title><source>Toxicol Appl Pharmacol</source><volume>224</volume><fpage>274</fpage><lpage>283</lpage><year>2007</year></element-citation></ref>
<ref id="b38-ijo-45-01-0104"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boocock</surname><given-names>DJ</given-names></name><name><surname>Faust</surname><given-names>GE</given-names></name><name><surname>Patel</surname><given-names>KR</given-names></name><etal/></person-group><article-title>Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent</article-title><source>Cancer Epidemiol Biomarkers Prev</source><volume>16</volume><fpage>1246</fpage><lpage>1252</lpage><year>2007</year></element-citation></ref>
<ref id="b39-ijo-45-01-0104"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vanamala</surname><given-names>J</given-names></name><name><surname>Reddivari</surname><given-names>L</given-names></name><name><surname>Radhakrishnan</surname><given-names>S</given-names></name><name><surname>Tarver</surname><given-names>C</given-names></name></person-group><article-title>Resveratrol suppresses IGF-1 induced human colon cancer cell proliferation and elevates apoptosis via suppression of IGF-1R/Wnt and activation of p53 signaling pathways</article-title><source>BMC Cancer</source><volume>10</volume><fpage>238</fpage><year>2010</year></element-citation></ref>
<ref id="b40-ijo-45-01-0104"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gweon</surname><given-names>EJ</given-names></name><name><surname>Kim</surname><given-names>SJ</given-names></name></person-group><article-title>Resveratrol induces MMP-9 and cell migration via the p38 kinase and PI-3K pathways in HT1080 human fibrosarcoma cells</article-title><source>Oncol Rep</source><volume>29</volume><fpage>826</fpage><lpage>834</lpage><year>2013</year></element-citation></ref>
<ref id="b41-ijo-45-01-0104"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hsu</surname><given-names>CP</given-names></name><name><surname>Kao</surname><given-names>TY</given-names></name><name><surname>Chang</surname><given-names>WL</given-names></name><name><surname>Nieh</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>HL</given-names></name><name><surname>Chung</surname><given-names>YC</given-names></name></person-group><article-title>Clinical significance of tumor suppressor PTEN in colorectal carcinoma</article-title><source>Eur J Surg Oncol</source><volume>37</volume><fpage>140</fpage><lpage>147</lpage><year>2011</year></element-citation></ref>
<ref id="b42-ijo-45-01-0104"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>BC</given-names></name><name><surname>Gao</surname><given-names>JL</given-names></name><name><surname>Luo</surname><given-names>X</given-names></name><etal/></person-group><article-title>Ginsenoside Rg3 inhibits colorectal tumor growth through the down-regulation of Wnt/&#x003B2;-catenin signaling</article-title><source>Int J Oncol</source><volume>38</volume><fpage>437</fpage><lpage>445</lpage><year>2011</year></element-citation></ref></ref-list>
<sec sec-type="display-objects">
<title>Figures</title>
<fig id="f1-ijo-45-01-0104" position="float">
<label>Figure 1.</label>
<caption>
<p>Resveratrol (Res) inhibits the proliferation of colon cancer cells. (A) Res inhibits the proliferation of HCT116 cells. Cells were seeded in 24-well plates and treated with different concentrations of Res or solvent, followed by crystal violet staining at the indicated time point. The crystal violet results were quantified as indicated in Materials and methods. <sup>&#x0002A;</sup>P&lt;0.05 vs. control group; <sup>&#x0002A;&#x0002A;</sup>P&lt;0.01 vs. control group. (B) Res inhibits the proliferation of SW480 cells. This assay was carried out as described in (A). <sup>&#x0002A;</sup>P&lt;0.05 vs. control group; <sup>&#x0002A;&#x0002A;</sup>P&lt;0.01 vs. control group. (C) Res arrests the cell cycle at G1 phase in HCT116 cells. (D) Res decreases the protein level of PCNA in HCT116 cells. Each condition was done in triplicate.</p></caption>
<graphic xlink:href="IJO-45-01-0104-g00.tif"/></fig>
<fig id="f2-ijo-45-01-0104" position="float">
<label>Figure 2.</label>
<caption>
<p>Resveratrol (Res) induces apoptosis in colon cancer cells. (A) Res induces apoptosis in HCT116 cells. Cells were seeded in 24-well plates and treated with different concentrations of Res for 48 h, then the cells were washed with PBS and incubated with Annexin V-EGFP. Images were taken with a fluorescent microscope. (B) Res induces apoptosis in HCT116 cells. Cells were seeded in 6-well plates and treated with different concentrations of Res for 48 h. Then, the cells were harvested and stained with Annexin V-EGFP and PI, followed by flow cytometry analysis. (C) Res increases the protein level of caspase-3 in HCT116 cells. Cells were seeded in 6-well plates and treated with different concentrations of Res. Total proteins were harvested after treating for 24 and 48 h, followed by western blot assay as described in Materials and methods. GAPDH was used as loading control. Each condition was done in triplicate.</p></caption>
<graphic xlink:href="IJO-45-01-0104-g01.tif"/></fig>
<fig id="f3-ijo-45-01-0104" position="float">
<label>Figure 3.</label>
<caption>
<p>Resveratrol (Res) inhibits xenograft tumor growth of colon cancer. (A) Representative tumor masses from xenograft tumor assay. HCT116 cells were injected into the flanks of athymic nude mice (five mice per group, 1&#x000D7;10<sup>6</sup> cells per injection). Res was intragastrically administered one week after cancer cell injection (50 or 150 mg/kg), once a day for four weeks. The mice were sacrificed at the end of the fourth week after injection, and the tumor masses were harvested for histologic analysis. (B) Histological examination of the xenograft tumor masses. Retrieved tumor masses were fixed, embedded and subjected to hematoxylin and eosin staining. Representative images are shown.</p></caption>
<graphic xlink:href="IJO-45-01-0104-g02.tif"/></fig>
<fig id="f4-ijo-45-01-0104" position="float">
<label>Figure 4.</label>
<caption>
<p>PTEN participates in the anti-proliferation effect of resveratrol (Res) in HCT116 cells. (A) Res upregulates the mRNA expression of PTEN. HCT116 cells were treated with different concentrations of Res or solvent. Total RNA were extracted at the indicated time point, followed by RT-PCR assay as described in Materials and methods. (B) Res increases the protein level of PTEN. HCT116 cells were treated with different concentrations of Res or solvent. Total protein was harvested at the indicated time point, followed by western blot assay as described in Materials and methods. GAPDH was used as loading control. (C) PTEN specific inhibitor partly reverses the anti-proliferation activities of Res in HCT116 cells. Cells were seeded in 24-well plates, treated with different concentrations of Res or combined with PTEN inhibitor (2 or 4 nM). (D) Exogenous expression or knockdown of PTEN affects the anti-proliferation activities of Res in HCT116 cells. Cells were seeded in 24-well plates, treated with different concentrations of Res or combined with infection of corresponding recombinant adenovirus (Ad-PTEN or Ad-siPTEN). The crystal violet stain and quantification were performed as described in Materials and methods. Each condition was done in triplicate.</p></caption>
<graphic xlink:href="IJO-45-01-0104-g03.tif"/></fig>
<fig id="f5-ijo-45-01-0104" position="float">
<label>Figure 5.</label>
<caption>
<p>Resveratrol (Res) inhibits PI3K/Akt signaling in HCT116 cells. (A) The effect of Res on the mRNA expression of Akt1 and Akt2. HCT116 cells were treated with different concentrations of Res or solvent, total RNA was harvested and RT-PCR performed to detect the expression of mRNA as described in Materials and methods. (B) Res decreases the phosphorylation of Akt1/2. HCT116 cells were treated with different concentrations of Res or solvent, combined with Ad-GFP. Total protein was harvested at the indicated time point, followed by western blot assay as described in Materials and methods. (C) Exogenous expression of PTEN enhances the inhibition of PI3K/Akt signaling induced by Res. HCT116 cells were treated with different concentrations of Res or solvent, combined with exogenous expression of PTEN (mediated by Ad-PTEN). Total protein was harvested at the indicated time point, followed by western blot assay as described in Materials and methods. (D) Knockdown of PTEN reverses the inhibition of PI3K/Akt signaling induced by Res. HCT116 cells were treated with different concentrations of Res or solvent, combined with recombinant adenovirus Ad-siPTEN. Total protein was harvested at the indicated time point, followed by western blot assay as described in Materials and methods. GAPDH was used as loading control. Each condition was done in triplicate.</p></caption>
<graphic xlink:href="IJO-45-01-0104-g04.tif"/></fig>
<fig id="f6-ijo-45-01-0104" position="float">
<label>Figure 6.</label>
<caption>
<p>Resveratrol (Res) inhibits Wnt/&#x003B2;-catenin signaling transduction in HCT116 cells. (A) Res decreases the phosphorylation of GSK-3&#x003B2; and the protein level of &#x003B2;-catenin. HCT116 cells were treated with different concentrations of Res or solvent. Total protein was harvested at the indicated time point, followed by western blot assay as described in Materials and methods. (B) Res inhibits the &#x003B2;-catenin/Tcf reporter activity. Cells were seeded in T25 flasks and transfected with 3.0 <italic>&#x003BC;</italic>g per flask of pTOP-Luc (&#x003B2;-catenin/TCF4 reporter plasmid) using Lipofectamine. After 12 h, cells were replated in 24-well plates and treated with different concentrations of Res or solvent as control. After 24 h, cells were lysed and subjected to luciferase activity assays. <sup>&#x0002A;</sup>P&lt;0.05 vs. control group; <sup>&#x0002A;&#x0002A;</sup>P&lt;0.01 vs. control group. (C) Res decreases the mRNA expression of &#x003B2;-catenin. HCT116 cells were treated with different concentrations of Res or solvent for 24 h. Total RNA was run on RT-PCR to detect the mRNA expression of &#x003B2;-catenin. (D) The effect of recombinant adenovirus on the expression of PTEN. HCT116 cells were seeded in a 6-well plate and infected with Ad-GFP, Ad-PTEN and Ad-siPTEN. After 24 h, total protein was harvested for western blotting to measure the expression of PTEN. Each condition was done in triplicate.</p></caption>
<graphic xlink:href="IJO-45-01-0104-g05.tif"/></fig></sec></back></article>
